Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 34Prostatic Neoplasms, Castration-Resistant 3Metastatic Castration-resistant Prostate Cancer 2Metastatic Castration-Resistant Prostate Cancer 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Prostate Cancer Metastatic Disease 1Prostate Adenocarcinoma 1Newly Diagnosed Oligometastatic Prostate Cancer 1Neoadjuvant Therapy 1Metastatic Hormone-sensitive Prostate Cancer 1Melanoma 1Disease 1Castration-resistant Prostate Cancer 1Castrate Sensitive Prostate Cancer 1Carcinoma, Small Cell 1Carcinoma, Non-Small-Cell Lung 1Anus Neoplasms 1

Interventions

pamiparib 1enzalutamide 1apalutamide 1abiraterone 1Prednisone 1Prednisolone 1Poly(ADP-ribose) Polymerase Inhibitors 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoadjuvant Therapy × abiraterone × Clear all
NCT05376722 2023-01-05

A Study of Pamiparib Combined With Abiraterone Acetate in Neoadjuvant Treatment of Prostate Cancer

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2 Unknown
30 enrolled

Neoadjuvant Therapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡